Home > Analytics > MANGALAM DRUGS & ORGANICS

MANGALAM DRUGS & ORGANICS
Intrinsic Value | Fundamental Analysis

BOM : 532637     NSE : MANGALAM    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
Dec 02,2022
Price(EOD): ₹ 143.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 226.10 Cr
Value of ₹ 1 Lac invested in MANGALAM DRUGS & ORGANICS
on Dec 04,2017 (price: ₹ 169.05)

₹ 1 L

₹ 0.85 L

1W : 7.3% 1M : 5.9% 1Y : 17.4%
COMMUNITY POLL
for MANGALAM DRUGS & ORGANICS
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
MANGALAM DRUGS & ORGANICS 7.3% 5.9% 17.4%
SUN PHARMACEUTICAL INDUSTRIES 0.6% -1.1% 38.8%
DIVIS LABORATORIES 0.2% -10.6% -30.7%
DR REDDYS LABORATORIES 2.5% -1% -5.8%
CIPLA 1% -4% 15.8%
GLAND PHARMA -1.3% -8.4% -51.1%
PIRAMAL ENTERPRISES 4.8% 2.6% -64.3%
CADILA HEALTHCARE 4.1% -4.8% -11.6%
TORRENT PHARMACEUTICALS -0.9% -4.3% 7.9%

FUNDAMENTAL ANALYSIS OF MANGALAM DRUGS & ORGANICS

 
Fundamentals Score
[ Q(TTM): Sep2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF MANGALAM DRUGS & ORGANICS

 
Valuation Score
[As on : Dec 02,2022 ]

Ratio Standalone
P/E
P/B
P/S
14.21
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 15.95 Cr
[Latest Qtr - Sep2022 - Standalone Results ]

1.5
P/B Calculated based on Book Value of Rs 150.56 Cr
[Latest Year - Mar2022 - Standalone Results ]

0.52
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2022 - Standalone Results ]

Financial Ratios →

Insights 💡 There are potential 16% undervalued companies ! Discover More →

FAIR VALUE OF MANGALAM DRUGS & ORGANICS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
310%
49%
230%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF MANGALAM DRUGS & ORGANICS



MANGALAM DRUGS & ORGANICS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF MANGALAM DRUGS & ORGANICS

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.52
0.49
0.48
0.5
-
-
-
-
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF MANGALAM DRUGS & ORGANICS

Pledged Promoter Shares
16.22 %
As on : Sep2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF MANGALAM DRUGS & ORGANICS

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-1.07%
-18.73%
-26.35%
-25.92%
-11.95%
-38.72%
-62.3%
-50.83%
QtrlyTrend
-8
Latest Qtr: Sep2022
Quarterly Result Analysis →


MANGALAM DRUGS & ORGANICS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about MANGALAM DRUGS & ORGANICS


Is MANGALAM DRUGS & ORGANICS good for long term investment?

As on Dec 02,2022, the Fundamentals of MANGALAM DRUGS & ORGANICS look Poor and hence it may not be good for long term investment ! See Financial Performance of MANGALAM DRUGS & ORGANICS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is MANGALAM DRUGS & ORGANICS UnderValued or OverValued?

As on Dec 02,2022, MANGALAM DRUGS & ORGANICS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of MANGALAM DRUGS & ORGANICS ?

As on Dec 02,2022, the Intrinsic Value of MANGALAM DRUGS & ORGANICS is Rs. 43.35 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 34.87
Fair Value [Median EV / Sales Model] : Rs. 95.86
Fair Value [Median Price / Sales Model] : Rs. 43.35
Estimated Median Fair Value of MANGALAM DRUGS & ORGANICS : Rs. 43.35

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is MANGALAM DRUGS & ORGANICS trading at a Premium or Discount?

As on Dec 02,2022, MANGALAM DRUGS & ORGANICS is trading at a Premium of 230% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].